People living with type 2 diabetes may face a significantly higher risk of developing dementia, including Alzheimer’s disease, according to a new literature review published in the Tungs’ Medical Journal. The findings point to a growing body of evidence that poor blood sugar control does not just affect the body, but may also cause lasting harm to the brain.
The review introduces the concept of “type 3 diabetes”, a term used by researchers to describe a state in which the brain itself becomes resistant to insulin. Insulin is not only crucial for regulating blood sugar throughout the body; it also plays a vital role in memory, learning, and the survival of nerve cells. When the brain stops responding to insulin properly, the consequences can include the build-up of amyloid plaques and tau tangles, both of which are hallmarks of Alzheimer’s disease.
The connection between obesity, type 2 diabetes, and cognitive decline has been recognised for some time, but this review draws together recent molecular and neuroimaging research to show just how closely linked these conditions are. People with type 2 diabetes are estimated to have around a 60% higher incidence of dementia. The onset of diabetes typically precedes the development of dementia by some years, which suggests a window during which intervention may still make a difference.
Hormonal factors also appear to play a role in who is most at risk. Women are disproportionately affected, with two-thirds of adults diagnosed with dementia being female according to data cited in the review. Declining oestrogen levels after the menopause have been linked to increased weight gain and greater metabolic vulnerability, which may contribute to this imbalance. For men, testosterone appears to offer some degree of protection against both obesity and diabetes.
Inflammation is another key mechanism the review highlights. Chronic low-grade inflammation, common in people with obesity and type 2 diabetes, can weaken the blood-brain barrier and allow harmful substances to enter the central nervous system. This neuroinflammation may accelerate the kind of cognitive decline associated with dementia. The Western diet, high in fat and sugar, is identified as a major driver of this inflammatory state.
There is, however, reason for cautious optimism. The review points to emerging evidence that lifestyle changes, particularly adopting a Mediterranean-style diet and increasing physical activity, can reduce the risk of cognitive impairment. Newer diabetes treatments, including GLP-1 receptor agonists such as liraglutide and semaglutide, are also being investigated for their potential neuroprotective effects, with early results showing promise in reducing amyloid accumulation and supporting brain health.
Researchers stress that type 3 diabetes is not yet an official medical diagnosis, but the concept is gaining traction as a useful framework for understanding and potentially preventing one of the most feared conditions of later life.